The antitumor lignan Nortrachelogenin sensitizes prostate cancer cells to TRAIL-induced cell death by inhibition of the Akt pathway and growth factor signaling

Biochemical Pharmacology

Volumn 86, Issue 5, 2013, Pages 571-583

  Peuhu, Emilia ^a   Paul, Preethy ^a,b   Remes, Mika ^a   Holmbom, Thomas ^b   Eklund, Patrik ^b   Sjöholm, Rainer ^b   Eriksson, John E ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Dibenzylbutyrolactone; Lignans; Nortrachelogenin; Prostate cancer; Receptor tyrosine kinase; TRAIL

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; CASPASE 3; GROWTH FACTOR; INSULIN; LIGNAN; NORTRACHELOGENIN; PROTEIN KINASE B; SOMATOMEDIN C; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIZATION; SIGNAL TRANSDUCTION;

EID: 84884902625     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.05.026     Document Type: Article

References (56)

1. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
2. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010;20:87-90.
3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7. (Pubitemid 27148818)
4. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720-3. (Pubitemid 28311897)
5. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta. Key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25:329-37. (Pubitemid 43117618)
6. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15:4799-805.
7. Chen LH, Fang J, Li H, Demark-Wahnefried W, Lin X. Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway. Mol Cancer Ther 2007;6:2581-90. (Pubitemid 47480424)
8. Peuhu E, Rivero-Muller A, Stykki H, Torvaldson E, Holmbom T, Eklund P, et al. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis. Oncogene 2010;29:898-908.
9. Dixon RA. Phytoestrogens. Annu Rev Plant Biol 2004;55:225-61. (Pubitemid 38940932)
10. Adlercreutz H. Lignans and human health. Crit Rev Clin Lab Sci 2007;44:483-525. (Pubitemid 47619399)
11. Buck K, Zaineddin AK, Vrieling A, Linseisen J, Chang-Claude J. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr 2010;92:141-53.
12. Li D, Yee JA, Thompson LU, Yan L. Dietary supplementation with secoisolar-iciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Lett 1999;142:91-6. (Pubitemid 29281572)
13. Bylund A, Saarinen N, Zhang JX, Bergh A, Widmark A, Johansson A, et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo. Exp Biol Med (Maywood) 2005;230:217-23. (Pubitemid 40293695)
14. McCann MJ, Gill CI, Linton T, Berrar D, McGlynn H, Rowland IR. Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Mol Nutr Food Res 2008;52:567-80.
15. Saarinen NM, Wä rri A, Dings RP, Airio M, Smeds AI, Mäkelä S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer 2008;123:1196-204.
16. Lindahl G, Saarinen N, Abrahamsson A, Dabrosin C. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res 2011;71:51-60.
17. Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL, et al. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther 2008; 7:2212-23.
18. Hausott B, Greger H, Marian B. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol 2003;129:569-76. (Pubitemid 37363596)
19. Yokoyama T, Okano M, Noshita T, Funayama S, Ohtsuki K. Characterization of matairesinol as a potent inhibitor of casein kinase I in vitro. Biol Pharm Bull 2003;26:371-4. (Pubitemid 39663628)
20. Chen LH, Fang J, Sun Z, Li H, Wu Y, Demark-Wahnefried W, et al. Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells. J Nutr 2009;139:653-9.
21. Sharma PR, Shanmugavel M, Saxena AK, Qazi GN. Induction of apoptosis by a synergistic lignan composition from cedrus deodara in human cancer cells. Phytother Res 2008;22:1587-94.
22. Yoo JH, Lee HJ, Kang K, Jho EH, Kim CY, Baturen D, et al. Lignans inhibit cell growth via regulation of Wnt/beta-catenin signaling. Food Chem Toxicol 2010;48:2247-52.
23. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276:10767-74. (Pubitemid 38089250)
24. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-83. (Pubitemid 32955050)
25. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/ TRAIL. Oncogene 2010;29:4752-65.
26. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008;118:111-23.
27. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008;118:100-10.
28. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009;127:145-54.
29. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010;16:1701-8.
30. Willfö r S, Hemming J, Reunanen M, Eckerman C, Holmbom B. Lignans and lipophilic extractives in Norway spruce knots and stemwood. Holzforchung 2003;57:359-72.
31. Eklund P, Lindholm A, Mikkola JP, Smeds A, Lehtilä R, Sjöholm R. Synthesis of matairesinol, enterolactone and enterodiol from the natural lignan hydroxymatairesinol. Org Lett 2003;5:491-3. (Pubitemid 37141129)
32. Eklund P, Sjöholm R. Oxidative transformation of the natural lignan hydro-xymatairesinol with 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone. Tetrahe-dron 2003;59:4515-23. (Pubitemid 36703278)
33. Eklund P, Sundell F, Smeds A, Sjöholm R. Reactions of the natural lignan hydroxy-matairesinol in basic and acidic nucleophilic media - formation and reactivity of a quinone methide intermediate. Org Biomol Chem 2004;2:1-8.
34. Damon RE, Schlessinger RH, Blount JF. A short synthesis isostegane. J Org Chem 1979;41:3772-3.
35. Eklund P, Sillanpää R, Sjöholm R. Synthetic transformation of hydroxymatair-esinol from Norway spruce (Picea abies) to 7-hydroxysecoisolariciresinol, (+)- lariciresinol and (+)-cyclolariciresinol. J Chem Soc Perkin Trans1 2002;16: 1906-10. (Pubitemid 34993207)
36. Erdtman H. Konstitution der Harzphenole und deren biogenetische Zusam-menhänge I. Über Pinoresinol. Svensk Kemisk Tidsskrift 1934;46:229-33.
37. Ekman R, Willfö r S, Sjöholm R, Reunanen M, Mäki J, Lehtilä R, et al. Identifica-tion of the lignan northrachelogenin in knot and branch heartwood of Scots pine (Pinus sylvestris L). Holzforchung 2002;56:253-6. (Pubitemid 34614392)
38. Khamlach K, Dhal R, Brown E. Lignans. 13. Total syntheses of carinol carissanol and hydroxythujaplicatin methyl ether. Heterocycles 1990;31: 2195-9.
39. Eklund P, Riska A, Sjöholm R. Synthesis of R-imperanene from the natural lignan hydroxymatairesinol. J Org Chem 2002;67:7544-6. (Pubitemid 35176411)
40. Ummanni R, Jost E, Braig M, Lohmann F, Mundt F, Barett C, et al. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation. Mol Cancer 2011;10:129.
41. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009;69:8386-94.
42. Skjoth IH, Issinger OG. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 2006;28:217-29.
43. Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002;89:230-40. (Pubitemid 34158454)
44. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86. (Pubitemid 46510744)
45. Torrance SJ, Hoffmann JJ, Cole JR. Wikstromol, antitumor lignan from wik-stroemia foetida var oahuensis gray and wikstroemia uva-ursi gray (thyme-laeaceae). J Pharm Sci 1979;68:664-5. (Pubitemid 9214940)
46. Lee KH, Tagahara K, Suzuki H, Wu RY, Haruna M, Hall IH, et al. Antitumor agents 49 tricin, kaempferol-3-O-beta-D-glucopyranoside and (+)-nortrache- logenin, antileukemic principles from wikstroemia indica. J Nat Prod 1981; 44:530-5. (Pubitemid 12213147)
47. Saarinen NM, Penttinen PE, Smeds AI, Hurmerinta TT, Mäkelä SI. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J Steroid Biochem Mol Biol 2005;93:209-19. (Pubitemid 40602494)
48. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
49. Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, et al. Sesamin manifests chemopreventive effects through the suppression of NF-kappaB-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res 2010;8:751-61.
50. Corsini E, Dell'Agli M, Facchi A, De Fabiani E, Lucchi L, Boraso MS, et al. Enterodiol and enterolactone modulate the immune response by acting on nuclear factor-kappaB (NF-kappaB) signaling. J Agric Food Chem 2010; 58:6678-84.
51. Cosentino M, Bombelli R, Carcano E, Luini A, Marino F, Crema F, et al. Immunomodulatory properties of achyrocline satureioides (lam.) D.C. infu-sion: a study on human leukocytes. J Ethnopharmacol 2008;116:501-7.
52. Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M. Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 2010;105: 748-67.
53. Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 2009;106:1113-22.
54. Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate can- cer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010;285:14980-89.
55. Karasic TB, Hei TK, Ivanov VN. Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res 2010;316:1994-7.
56. Girnita A, All-Ericsson C, Economou MA, Astrom K, Axelson M, Seregard S, et al. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 2006;12:1383-91. (Pubitemid 43342532)